Heron Therapeutics Reaffirms FY24 Revenue $138.0M-$158.0M Vs $144.875M Est.
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics has reaffirmed its fiscal year 2024 revenue forecast to be between $138.0 million and $158.0 million, which is in line with the estimated $144.875 million.
May 07, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heron Therapeutics reaffirms its FY24 revenue guidance, indicating confidence in its financial outlook.
Reaffirming revenue guidance often signals to investors that a company is on track to meet or exceed its financial targets, which can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100